As the biologics landscape evolves, developers often face two converging pressures: the need to advance programs to the clinic faster and the growing prevalence of increasingly advanced therapeutic formats, such as bispecific antibodies, Fc-fusion proteins and high-concentration formulations. While these molecules offer new opportunities to address unmet patient needs, they can also introduce additional development and manufacturing considerations that challenge traditional timelines.
When Speed and Complexity Converge
In this on-demand presentation, explore how integrated development strategies, together with molecule- and phase-appropriate approaches, can help address these evolving demands and accelerate the path from DNA to IND. Through case studies and practical examples, discover the scientific and operational enablers that can support accelerated development, including cell line development, expression technologies, platform methods and coordinated CMC activities.
Learn how early development strategies can influence speed, scalability and regulatory readiness, and how an integrated approach can help reduce timelines while maintaining confidence in product quality and manufacturability.